ClinicalTrials.gg
CompletedNCT07095257ZX-7101A-214Updated Apr 16, 2026

Study to Assess the Safety and Efficacy of ZX-7101A for Oral Suspension in Chinese Pediatric Participants 2 to 11 Years of Age With Influenza

A Phase 3 interventional study of ZX-7101A for oral suspension and Oseltamivir phosphate for oral suspension in Respiratory Viral Infection, sponsored by Nanjing Zenshine Pharmaceuticals. Completed at 2 sites in China. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Nanjing Zenshine Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
169
Allocation
Randomized
Ages
2 Years to 11 Years
Sex
All
01

Study summary

The goal of this phase III study is to learn if ZX-7101A for oral suspension works to treat uncomplicated influenza in Pediatric Participants aged 2 to 11 years.

The main question it aims to answer is: What medical problems do participants have when taking drug ZX-7101A for oral suspension or Oseltamivir phosphate for oral suspension? Researchers will compare drug ZX-7101A for oral suspension to active comparator: Oseltamivir phosphate for oral suspension to see if drug ZX-7101A for oral suspension works to treat uncomplicated influenza in Pediatric Participants aged 2 to 11 years.

02

Conditions studied

  • Respiratory Viral Infection
03

In context

Lead sponsor

Nanjing Zenshine Pharmaceuticals is the lead sponsor of 16 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥2 to\<12 years of age at the time of randomization, males or females.
  • Patients in the screening period met the following criteria:

    1. Rapid influenza diagnostic test (RIDT) or polymerase chain reaction (PCR) test positive;
    2. Axillary temperature ≥ 37.5℃ at screening; If taking antipyretics, axillary temperature ≥ 37.5℃ after taking the drug (more than 4 hours).
    3. At least one of the influenza-related respiratory symptoms is moderate or greater in severity: nasal congestion/runny nose and coughing.
  • The first occurrence of influenza symptoms ≤ 48 hours from the time of patient randomization. The occurrence of symptoms is defined as:

    1. The body temperature first reached ≥ 37.5℃ (axillary/oral temperature) or 38.0℃ (rectal or tympanic temperature);
    2. Or the occurrence of at least one systemic or respiratory symptom: nasal congestion, sore throat, cough, muscle pain, headache, etc.
  • The guardian of the participants must agree to participate in the study and sign a written form. For participants aged 8 years old and above, they must sign the informed consent form voluntarily (for participant under the age of 8, only the informed consent form signed by the guardian is required.); The participant s and/or their guardians agree to comply with all study procedures, including filling out the participant diary cards (the guardians of the subjects may assist in the assessment/filling).

Exclusion criteria

Exclusion Criteria:

  • Patients with severe or critically influenza virus infection (Meet any one of the following criteria).

    1. Severe cases with any of the following conditions: Dyspnea and/or increased respiratory rate: more than 30 breaths per minute for children over 5 years old; over 40 times per minute for children aged 2 to 5.

      Changes in consciousness: slow response, drowsiness, restlessness, convulsions, etc.

      Severe vomiting or diarrhea, with signs of dehydration. oliguria: Children with urine output\<0.8 mL/(kg · h), or infants with daily urine output\<200 mL/m2, preschool children\<300 mL/m2, school aged children\<400 mL/m2, or experiencing renal failure;

    2. Critical cases with any of the following conditions (Including but not limited to): Respiratory failure; Acute necrotizing encephalomyopathy; Shock septic; Multiple organ dysfunction; Other serious clinical situations require intensive care Note: Refer to \<the Expert Consensus on Diagnosis and Treatment of Childhood Influenza (2020 Edition)>
  • High risk population for severe cases (meeting any of the following criteria):

    1. Accompanied by the following underlying diseases, and being according to researchers' judgment, such as lung diseases (asthma, tracheopulmonary dysplasia, cystic fibrosis, etc.), liver diseases, kidney diseases, hematological diseases, heart diseases (congenital heart disease, chronic congestive heart failure [ heart function classification III-IV], etc. But excluding hypertension without any other heart related symptoms), neurological and neuromuscular diseases that affect respiratory secretion clearance function (cognitive impairment, spinal cord injury, epileptic seizures, neuromuscular disorders, and cerebral palsy, etc), metabolic and endocrine system diseases.
    2. individuals, such as patients with malignant tumors, organ or bone marrow transplants, infections, or those who have been taking immunosuppressive drugs in the past 3 months.
    3. The shows clinically significant corrected interval abnormalities (QTc ≥ 460ms) (QT corrected interval calculated according to Fridericia's formula, i.e. QTcF).
    4. Subjects require long-term use of aspirin or salicylate containing defined as those who need to take aspirin or salicylate containing drugs regularly per day for more than 14 days.
    5. With a (BMI) exceeding the criteria outlined in Appendix 2 of this protocol; During the screening period, patients with clinically significant bronchitis, pneumonia, pleural effusion, or interstitial lesions that identified by the researchers. If the researcher deems it necessary, imaging examinations (chest X-ray or chest CT) can be performed.
  • Individuals who have experienced acute respiratory infections or otitis media and sinusitis within the past 2 weeks prior to screening.
  • Combined with other respiratory infections, or requiring systemic anti infection treatment, or blood routine examination during screening with white blood cell count (WBC)> (venous blood).
  • Coughing up purulent phlegm or suffering from purulent tonsillitis.
  • Have difficulty in swallowing medicine or have a history of gastrointestinal diseases that determined by researchers to seriously affect drug absorption.
  • Suspected allergy to the active ingredients or of the drug.
  • Have taken anti influenza virus drugs (including but not limited to: neuraminidase inhibitors, hemagglutinin inhibitors, M2 ion channel blockers, and cap structure dependent endonuclease (CEN) inhibitors, such as oseltamivir, zanamivir, paramivir, favipiravir, rimantadine, amantadine, abiidol, balosavir, etc.) within the past 7 days prior to screening.
  • Received live or attenuated vaccines within the first 2 weeks of randomization or subjects who have received influenza vaccine within the first 2 weeks of randomization;
  • Suspect or have a history of alcohol or drug abuse.
  • Positive in pregnancy test.
  • Participated in other clinical trials and used any other clinical trial drugs or devices within the 30 days prior to screening;
  • Determined by the researchers to be unsuitable for participation in this clinical study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
169 participants (actual)

Study arms

  • Experimental
    ZX-7101A for oral suspension

    A randomized phase III study with safety as primary endpoint was conducted in children (2-11 years old) with uncomplicated influenza. Eligible subjects were randomly assigned in a 2:1 ratio to receive either ZX-7101A for oral suspension (specification:10mg per bag)or oseltamivir phosphate for oral suspension (specification:0.36 g). Preparation of suspension solution ZX-7101A: the specification of the dry suspension is 10 mg per bag. Add 10 ml of warm water for each bag, Mix well and take it all at once as soon as possible. Administer the dosage according to body weight.

    Drug: ZX-7101A for oral suspension

  • Active comparator
    Oseltamivir phosphate for oral suspension

    A randomized phase III study with safety as primary endpoint was conducted in children (2-11 years old) with uncomplicated influenza. Eligible subjects were randomly assigned in a 2:1 ratio to receive either ZX-7101A for oral suspension (specification:10mg per bag)or oseltamivir phosphate for oral suspension (specification:0.36 g). Administer the medication according to the weight specified in the label.

    Drug: Oseltamivir phosphate for oral suspension

Interventions

  • ZX-7101A will be administered as oral suspension in a single dose on Day 1. Oseltamivir phosphate matching placebo will also be administered as oral suspension twice daily (BID) for 5 days.

  • Oseltamivir phosphate will be administered as oral suspension BID for 5 days. Participants receiving oseltamivir will also receive ZX-7101A matching placebo as oral suspension, single dose on Day 1.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0

    The Number of Participants with Treatment-Related Adverse Event will be evalated as the change of vital signs, electrocardiogram, physical examination, and Laboratory test compared with the baseline.

    Time frame: From day1 up to day15

Secondary outcomes

  1. Time to Alleviation of Influenza Signs and Symptoms

    Time to alleviation of influenza signs and symptoms is defined as the length of time taken from the start of treatment to the point at which all of the following criteria are met (Standard a or b) and remain so for at least 21.5 hours: 1. Body temperature returns to normal (axillary temperature ≤ 37.2℃) 2. In the CARIFS scale, a score of 0 (no problem) or 1 (minor problem) for cough ,rhinobyon or nasal symptoms.

    Time frame: From day1 up to day15

  2. Duration of fever

    Length of time taken by participants to return to afebrile state \[axillary temperature ≤ 37.2°C\] and remaining so for at least 21.5 hours.

    Time frame: From day1 up to day15

  3. Time to Alleviation of Symptoms

    Symptom recovery time: Defined as the period from the start of the study treatment until all 16 assessment items in the CARIFS were evaluated as being asymptomatic or mild, and remained so for at least 21.5 hours.

    Time frame: From day1 up to day15

  4. Time to Return to Normal Health and Activity

    Time to Return to Normal Health and Activity

    Time frame: From day1 up to day15

  5. The time influenza RNA turns negative

    Defined as the time from initiation of treatment until the first influenza viral RNA falls below the lower limit of quantification (measured by RT-PCR)

    Time frame: From day1 up to day15

  6. The time Virus Titer turns negative

    Defined as the time from initiation of treatment until the first viral titer falls below the lower limit of quantification

    Time frame: From day1 up to day15

  7. Change From Baseline in the Amount of Virus RNA (RT-PCR) and Influenza Virus Titer at each visit

    Change From Baseline in the Amount of Virus RNA (RT-PCR, unit: log10virus particles/mL) and Influenza Virus Titer (unit: log10TCID50/ML) at each visit

    Time frame: Baseline, Day 2,3,5,9,15

  8. Percentage of Participants With Positive Influenza Virus Titer at each visit (measured by RT-PCR)

    Percentage of Participants With Positive Influenza Virus Titer at each visit (measured by RT-PCR)(unit: %)

    Time frame: Baseline, Day 2,3,5,9,15

07

Study locations

2 sites
  • West China Second University Hospital, Sichuan University
    Chengdu, Sichuan, China
  • Children's Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2025 to primary completion in Jan 2026, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2025
First posted
Jul 31, 2025
StartActual
Oct 13, 2025
Primary completionActual
Jan 16, 2026
CompletionActual
Jan 16, 2026
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07095257
Lead sponsor
Nanjing Zenshine Pharmaceuticals
Responsible party
Sponsor
First posted
Jul 31, 2025
Start date
Oct 13, 2025
Primary completion
Jan 16, 2026
Completion
Jan 16, 2026
Last update
Apr 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ZX-7101A

Start the discussion